Feature News
Tessa at a Glance
Tessa on Twitter
4 weeks ago
Our CSO, John Connolly @hotirishmonkey speaks with Dr Jonathan Maltzman @StanfordMed about harnessing Regulatory T Cells and inhibiting them to fight cancer and other viral illnesses. Watch the interview: https://t.co/pk2uQj6k8B #immunotherapy #celltherapy #solvecancer https://t.co/mHIMRC1sss
Our CSO, John Connolly @hotirishmonkey speaks with Dr Jonathan Maltzman @StanfordMed about harnessing Regulatory T Cells and inhibiting them to fight cancer and other viral illnesses. Watch the interview: https://t.co/pk2uQj6k8B #immunotherapy #celltherapy #solvecancer https://t.co/mHIMRC1sss
2 months ago
Dr Göran Ando, who joined Tessa’s Board of Directors last April, recently shared his views on the potential of #celltherapy and the key ingredients needed to successfully translate early research efforts into patient treatments: https://t.co/dgntjqQ5Ub
Dr Göran Ando, who joined Tessa’s Board of Directors last April, recently shared his views on the potential of #celltherapy and the key ingredients needed to successfully translate early research efforts into patient treatments: https://t.co/dgntjqQ5Ub
Tessa’s Media Channel
In this second interview, our CSO, John Connolly speaks to Dr Jeffrey Bluestone, who is the President and CEO at the Parker Institute for Cancer Immunotherapy. Dr Bluestone discusses the impact of cell immunotherapy in changing the field of pharmaceutical drug development and the all-important role of cross-industry collaboration in the future success of cell therapies.